Resultats globals: 3 registres trobats en 0.01 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
11 p, 632.8 KB Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma / Vieito, María (Vall d'Hebron Institut d'Oncologia) ; Simonelli, Matteo (Humanitas Research Hospital (Itàlia)) ; de Vos, Filip (University Medical Center Utrecht) ; Geurts, Marjolein (Erasmus MC Cancer Institute (Holanda)) ; Lorenzi, Elena (Humanitas Research Hospital (Itàlia)) ; Macchini, Marina (San Raffaele Scientific Institute (Itàlia)) ; van den Bent, Martin J (Erasmus MC Cancer Institute (Holanda)) ; Del Conte, Gianluca (San Raffaele Scientific Institute (Itàlia)) ; de Jonge, Maja (Erasmus MC Cancer Institute (Holanda)) ; Martín-Soberón, Maria Cruz (Hospital Universitario 12 de Octubre (Madrid)) ; Amoroso, Barbara (A Bristol Myers Squibb Company (Sevilla)) ; Sanchez-Perez, Tania (Bristol Myers Squibb Company (Sevilla)) ; Zuraek, Marlene (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Hanna, Bishoy (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Aronchik, Ida (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Filvaroff, Ellen (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Chang, Henry (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Mendez, Cristina (Bristol Myers Squibb (Sevilla)) ; Arias Parro, Marina (Bristol Myers Squibb (Suïssa)) ; Wei, Xin (Bristol Myers Squibb (Estats Units d'Amèrica)) ; Nikolova, Zariana (Bristol Myers Squibb (Sevilla)) ; Sepulveda, Juan Manuel (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Standard-of-care treatment for newly diagnosed glioblastoma (ndGBM), consisting of surgery followed by radiotherapy (RT) and temozolomide (TMZ), has improved outcomes compared with RT alone; however, prognosis remains poor. [...]
2022 - 10.1093/noajnl/vdac146
Neuro-oncology Advances, Vol. 4 (october 2022)  
2.
14 p, 1.9 MB Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer / Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ; Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Calvo, Emiliano (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ; Seoane Suárez, Joan (Hospital Universitari Vall d'Hebron) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Cleverly, Ann (Eli Lilly and Company) ; Pillay, N. Sokalingum (Eli Lilly and Company) ; Desaiah, Durisala (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Paz-Ares, Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ; Blakeley, Jaishri (Johns Hopkins University) ; Lahn, Michael M.. (Eli Lilly and Company) ; Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370  
3.
16 p, 911.4 KB Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients / Molina García, David (Universidad de Castilla-La Mancha) ; Pérez Beteta, Julián (Universidad de Castilla-La Mancha) ; Martínez González, Alicia (Universidad de Castilla-La Mancha) ; Sepúlveda, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ; Peralta, Sergi (Hospital Universitari Sant Joan de Reus (Tarragona)) ; Gil-Gil, Miguel (Institut Català d'Oncologia) ; Reynes, Gaspar (Hospital Universitari i Politècnic La Fe (València)) ; Herrero, Ana (Hospital Universitario Miguel Servet (Saragossa)) ; de las Peñas, Ramon (Consorci Hospitalari Provincial de Castelló) ; Luque, Raquel (Hospital Universitario Virgen de las Nieves (Granada)) ; Capellades, Jaume (Hospital del Mar (Barcelona, Catalunya)) ; Balañá, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pérez García, Víctor M. (Universidad de Castilla-La Mancha)
Background: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. [...]
2016 - 10.1371/journal.pone.0161484
PloS one, Vol. 11 Núm. 8 (August 2016)  

Vegeu també: autors amb noms similars
1 Sepulveda, Juan Manuel
1 Sepúlveda, Juan Carlos
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.